Drug Profile
Adrulipase alfa - First Wave BioPharma/Mayoly-Spindler
Alternative Names: Adrulipase; MS-1819; MS1819-SD; Recombinant lipase - First Wave BioPharma/Mayoly-SpindlerLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Mayoly-Spindler
- Developer First Wave BioPharma; Mayoly-Spindler
- Class Anti-inflammatories; Carboxylic ester hydrolases; Pancreatic enzymes; Recombinant proteins
- Mechanism of Action Lipase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Exocrine pancreatic insufficiency; Pancreatitis
Most Recent Events
- 05 Apr 2024 First Wave Biopharma announced intention to schedule a Type C meeting with the FDA in the first half of 2024 (First Wave BioPharma SEC 2024)
- 31 Dec 2023 First Wave Biopharma has patents pending for Adrulipase formulations in USA (First Wave BioPharma SEC 2024)
- 13 Jul 2023 First Wave Biopharma plans to conduct the end-of-phase II meeting with the US FDA in the fourth quarter of 2023